New research published in PNAS that was led by investigators at Massachusetts General Hospital (MGH) and the University of Geneva (UNIGE) provides insights on why some types of colorectal cancer don’t respond to immune checkpoint inhibitors and offers a strategy to overcome their resistance.
Celiac Disease Program
Charles River Plaza
165 Cambridge Street, 9th Floor
Boston, MA 02114
Hours: Monday–Friday, 8:00 am–5:00 pm
Services also available at:
Mass General North Shore Center for Outpatient Care
102-104 Endicott Street
Danvers, MA 01923
Explore This Program
A Multidisciplinary Approach to Care
The prevalence of celiac disease in the U.S. has quadrupled over the past 50 years. The Celiac Disease Program at Mass General brings together an expert team of providers who work with patients with celiac disease to co-create health.
This multi-disciplinary care team is tailored to each patient’s unique condition. Our providers include:
- GI pathologists
- GI radiologists
- Food allergy specialists
We offer the full range of endoscopic diagnostic procedures critical for obtaining a tissue diagnosis and differentiating celiac disease from other disorders such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), microscopic colitis (lymphocytic and collagenous), eosinophilic and autoimmune enteritis, and irritable bowel syndrome (IBS).
Patient Education and Support
Patient education and support are important components of our mission. We are committed to helping patients understand their disease, assess their treatment options, participate in their treatment decisions and feel in control of their disease. Our physicians are experienced in fine-tuning medical therapies and helping patients obtain relief from persistent, difficult-to-manage symptoms.
To help educate the community about how our diet, lifestyle and environment can affect GI health, our doctors participate in community events throughout the year.
Advancing an Understanding of Celiac Disease through Ongoing Research
The Celiac Disease Program at Mass General is a comprehensive program dedicated to the diagnosis and treatment of patients with celiac disease and all gluten-mediated disorders. The gastroenterology department at Massachusetts General Hospital is consistently ranked among the nation's top programs, with Magnet award-winning nurses providing patients with compassionate, timely care. Magnet designation represents the highest honor available for nursing excellence and is achieved by fewer than 7% of hospitals in the United States. Our multidisciplinary team of providers has been recognized both nationally and internationally for groundbreaking research and outstanding patient care.
We believe that each patient can significantly improve our knowledge of celiac disease and contribute toward understanding the factors that influence the development of this disease and factors that determine response to treatments. All of the physicians involved in the Celiac Disease Program actively participate in research programs aimed at understanding the underlying cause of celiac disease, with the goal of developing more effective treatment approaches.
Dr. Ramnik Xavier directs a research program that focuses on understanding the genetic basis of celiac disease based on genome-wide association studies. Dr. Xavier's research group actively collaborates with the lab of Dr. Cisca Wijmenga, a world leader in the genetics of celiac disease. In addition, Dr. Xavier works closely with Dr. Bana Jabri, a renowned immunologist who is working with Dr. Xavier to develop systems biology approaches to understanding the fundamental mechanisms underlying celiac disease.
- Sep | 10 | 2021
“Each morning when we’d arrive at the police barricades, people would be standing there with pictures of their loved ones, asking us to look for them,” Susan Diehl says. “Hours later, after a hard shift when we were ready to get back on the shuttle bus, they were still there—waiting for word.”
- Press Release
- Aug | 27 | 2021
A new health and economic model clearly shows why it’s imperative that food manufacturers reduce the amount of added sugar in their products.
- Jul | 12 | 2021
Immunotherapy is a cancer treatment that works by boosting the body’s immune system. Some patients achieve full remission, meaning all signs of their cancer have disappeared.
- Press Release
- Jul | 8 | 2021
Las puntuaciones de riesgo genético podrían mejorar la identificación clínica de los pacientes con mayor riesgo de infarto
Un equipo descubrió recientemente que la aplicación de la PRS puede identificar a los pacientes de riesgo que actualmente no se identifican mediante las evaluaciones clínicas estándar.
- Press Release
- Jul | 2 | 2021
Using a method developed for HIV, researchers have identified stable T cell vaccine targets in SARS-CoV-2.